Sugi Predict

Sugi Predict / Targets / DYRK1B

DYRK1B

Dual specificity tyrosine-phosphorylation-regulated kinase 1B · Q9Y463 · DYRK1B on Sugi Atlas →

96,466 patent compounds predicted against DYRK1B, 60,379 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL102235 SCHEMBL102235 1.00 18/20
SCHEMBL102656 SCHEMBL102656 0.79 18/20
SCHEMBL102951 SCHEMBL102951 0.76 18/20
SCHEMBL102660 SCHEMBL102660 0.75 18/20
SCHEMBL102233 SCHEMBL102233 1.00 17/20
SCHEMBL102955 SCHEMBL102955 1.00 17/20
SCHEMBL103266 SCHEMBL103266 0.85 17/20
SCHEMBL102650 SCHEMBL102650 0.76 17/20
SCHEMBL102236 SCHEMBL102236 0.75 15/20
SCHEMBL102764 SCHEMBL102764 0.75 15/20
SCHEMBL102239 SCHEMBL102239 0.70 15/20
SCHEMBL102952 SCHEMBL102952 0.76 14/20
SCHEMBL102225 SCHEMBL102225 0.72 14/20
SCHEMBL102240 SCHEMBL102240 0.67 14/20
SCHEMBL103262 SCHEMBL103262 0.67 14/20
SCHEMBL103265 SCHEMBL103265 1.00 13/20
SCHEMBL102507 SCHEMBL102507 0.78 13/20
SCHEMBL102940 SCHEMBL102940 0.78 13/20
SCHEMBL102984 SCHEMBL102984 0.77 13/20
SCHEMBL102942 SCHEMBL102942 1.00 12/20

Clinical trials — most relevant to DYRK1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer PHASE4RECRUITING
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer PHASE3UNKNOWN
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy PHASE2ACTIVE_NOT_RECRUITING
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer PHASE2RECRUITING
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer PHASE2RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study nanCOMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DYRK1B binder may also engage these)

ProteinNameSimilarity
Q9Z188 — 1.000 Q9Z188 →
Q4V793 — 0.995 Q4V793 →
Q9Z2A6 — 0.995 Q9Z2A6 →
Q3V016 — 0.994 Q3V016 →
Q63553 — 0.994 Q63553 →
Q6NSM8 — 0.993 Q6NSM8 →
Q8WP28 — 0.993 Q8WP28 →
Q3ULB5 — 0.993 Q3ULB5 →
HIPK4 Homeodomain-interacting protein kinase 4 0.992 landscape →
Q8CIP4 — 0.992 Q8CIP4 →
Q80Y86 — 0.992 Q80Y86 →
Q4V8A3 — 0.992 Q4V8A3 →
A5PKJ4 — 0.991 A5PKJ4 →
Q60700 — 0.991 Q60700 →
Q2NL51 — 0.991 Q2NL51 →
Q66HE5 — 0.991 Q66HE5 →
Q68UT7 — 0.991 Q68UT7 →
Q641K5 — 0.991 Q641K5 →
Q8VDU5 — 0.990 Q8VDU5 →
Q9WVS8 — 0.990 Q9WVS8 →
O70405 — 0.990 O70405 →
RXRB Retinoic acid receptor RXR-beta 0.989 landscape →
Q5R8Z4 — 0.989 Q5R8Z4 →
Q924U5 — 0.989 Q924U5 →
Q9H329 — 0.989 Q9H329 →
Q61214 — 0.989 Q61214 →
Q60670 — 0.989 Q60670 →
B8Y466 — 0.989 B8Y466 →
Q6P4S6 — 0.989 Q6P4S6 →
Q9D176 — 0.989 Q9D176 →